Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma

It is now clear that angiogenesis and angiogenesis factors are important in the pathogenesis of haematological malignancies. High pretreatment levels of serum basic fibroblast growth factor have been shown to be associated with poor prognosis in patients with non-Hodgkin's lymphoma. The aim of this study was to evaluate whether non-Hodgkin's lymphoma cells express basic fibroblast growth factor and/or its receptor (fibroblast growth factor receptor-1) and whether basic fibroblast growth factor expression correlates with basic fibroblast growth factor serum levels, intratumoral microvessel density, and patient outcome. We measured basic fibroblast growth factor by enzyme-linked immunosorbent assay in sera taken from 58 patients with non-Hodgkin's lymphoma before treatment and in 19 of them also after treatment. Pathological specimens at diagnosis were evaluated by immunohistochemistry staining using polyoclonal antibody against factor-VIII-related antigen, basic fibroblast growth factor and fibroblast growth factor receptor-1 to determine the expression of the microvessel count and basic fibroblast growth factor and fibroblast growth factor receptor-1. The lymphoma specimens demonstrated positive staining for basic fibroblast growth factor (in 23%) and fibroblast growth factor receptor-1 (in 58.5%). The patients who expressed basic fibroblast growth factor had a significantly worse progression-free and overall survival than those who did not (P=0.003 and P=0.03 respectively), while patients expressing fibroblast growth factor receptor-1 were less likely to achieve complete remission than those lacking the receptor (33% vs 65% , P=0.047). There was no correlation of basic fibroblast growth factor staining with either serum basic fibroblast growth factor levels or microvessel count. Basic fibroblast growth factor serum levels did not change significantly after treatment These results suggest that non-Hodgkin's lymphoma specimens express basic fibroblast growth factor and its receptor (fibroblast growth factor receptor-1) and this expression is associated with poor patient outcome

Modeling the adsorption of mixed gases based on pure gas adsorption properties

Sorption-based Joule-Thomson (JT) cryocoolers usually operate with pure gases. A sorption-based compressor has many benefits; however, it is limited by the pressure ratios it can provide. Using a mixed-refrigerant (MR) instead of a pure refrigerant in JT cryocoolers allows working at much lower pressure ratios. Therefore, it is attractive using MRs in sorption-based cryocoolers in order to reduce one of its main limitations. The adsorption of mixed gases is usually investigated under steady-state conditions, mainly for storage and separation processes. However, the process in a sorption compressor goes through various temperatures, pressures and adsorption concentrations; therefore, it differs from the common mixed gases adsorption applications. In order to simulate the sorption process in a compressor a numerical analysis for mixed gases is developed, based on pure gas adsorption characteristics. The pure gas adsorption properties have been measured for four gases (nitrogen, methane, ethane, and propane) with Norit-RB2 activated carbon. A single adsorption model is desired to describe the adsorption of all four gases. This model is further developed to a mixed-gas adsorption model. In future work more adsorbents will be tested using these four gases and the adsorption model will be verified against experimental results of mixed-gas adsorption measurements